- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
Stem Cell Trial May Resume Soon
28 August 2009 12:13 pm
Geron Corp. has revealed why the Food and Drug Administration halted its much-heralded Phase I clinical trial using embryonic stem cells to treat spinal cord injury 2 weeks ago. The reason: "non-proliferative cysts." In a statement issued yesterday, the company explained that in their ongoing animal studies, a small number of those injected with the stem cell preparation had developed tiny cysts at the injury site.
But not to worry, says Geron. That's actually good news. Spinal cord patients routinely develop much larger cysts. More significantly, there is no sign that the stem cell treatment causes tumors in the animals. And animal tests with a new batch of GRNOPC1, the stem cell preparation, showed no cysts. Geron officials expressed confidence that the trial will soon be back on track.